|
|
|
PER.C6 Technology from Crucell Could Soon Herald Lowered Costs for Antibody Treatments
|
|
By HCat at 2007-02-21 02:40
|
PER.C6 Technology from Crucell Could Soon Herald Lowered Costs for Antibody Treatments
   Crucell in a partnership with DSM have announced that production of monoclonal antibodies has reached 10g/L (grams per liter) of cell culture, using the PER.C6 platform to produce the yields. Current standard methods yield monoclonal antibodies around 1-2g/L. This order of magnitude increase in yield could help lower the cost for producing the current monoclonal antibodies used in treatments for cancer today. The price of drugs has soared for cancer treatment and the monoclonal antibodyterm is no exception. Herceptin costs around $3,000 a month, Avastinterm is at $4,400, Erbituxterm costs around $10,000 a month, and Rituxanterm can range from $4,200 to $13,000 a month depending on treatment. A great article on recent drug costs can be found here on the USA Today site.
   The PER.C6 technology is based on the human retina cells. A human retina cell was transformed and immortalized with adenovirus DNA. This allowed the cell to grow indefinitely. Recombining new DNA into the transformed cell allows the production of proteins encoded in the DNA. Antibodies can also be made by creating a hybridoma. The antibodies produced are functional and meet industry standards, since these cells can be grown in controlled media without the presence of serum.
The press release can be found here.
A description of the PER.C6 technology can be found here.
|
|
2353 reads
|
|
|
|
sponsored links
|
|
|
|
All times are GMT -5. The time now is 03:15 AM.
Register
add to favorites